Icatibant Fresenius

Icatibant acetate, the active ingredient in Icatibant Fresenius, is a bradykinin B2 receptor antagonist presented as a subcutaneous formulation for subcutaneous use. It treats acute attacks of hereditary angioedema in patients with C1‑inhibitor deficiency. GNH USA supplies Icatibant Fresenius as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Icatibant Fresenius is used to manage conditions driven by excessive bradykinin activity, especially hereditary angioedema. - Hereditary angioedema type I attacks: Rapid reduction of swelling and associated pain. - Hereditary angioedema type II attacks: Prompt relief of edema and restoration of airway patency. - Hereditary angioedema with normal C1‑inhibitor: Accelerates resolution of acute swelling episodes.

Icatibant Fresenius may cause a range of adverse reactions following subcutaneous administration.

Common Side Effects: - Injection site erythema: Redness at the injection site. - Injection site pain: Localized discomfort after dosing. - Injection site swelling: Mild to moderate edema around the needle entry. - Nausea: Transient feeling of queasiness. - Headache: Mild to moderate head pain.

Serious or Rare Side Effects: - Anaphylactic reaction: Rapid onset of systemic hypersensitivity requiring emergency care. - Severe hypotension: Marked drop in blood pressure that may lead to dizziness or syncope. - Laryngeal edema: Swelling of the throat that can compromise airway patency. - Stevens‑Johnson syndrome: Rare severe skin reaction with blistering and detachment.

Before using Icatibant Fresenius, consider the following safety measures. - Renal impairment: Monitor renal function and adjust therapy if needed. - Hepatic impairment: Use with caution in patients with liver disease. - Pregnancy: Safety not established; prescribe only if benefit outweighs potential risk. - Breastfeeding: Unknown excretion in milk; evaluate risk versus benefit. - Concomitant ACE inhibitors: May increase bradykinin levels and risk of angioedema. - Store at 2-8°C: Keep refrigerated, protect from light, do not freeze or shake.

Icatibant Fresenius can interact with other medicines that influence bradykinin pathways or vascular tone.

Major Interactions (Avoid): - ACE inhibitors: Heightened risk of angioedema; avoid co‑administration. - Angiotensin II receptor blockers (ARBs): May augment bradykinin effects; avoid. - Estrogen‑containing contraceptives: Can exacerbate hereditary angioedema; avoid.

Moderate Interactions (Monitor Closely): - C1‑inhibitor concentrates: Potential reduction in therapeutic effect; monitor response. - Other bradykinin‑targeting agents: Additive pharmacodynamic effect; observe for excessive hypotension. - Non‑steroidal anti‑inflammatory drugs (NSAIDs): May increase local injection‑site reactions; watch for irritation.